Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 04.02.2019 1 Am J Surg 2 Ann Oncol 3 Ann Surg Oncol 3 BMC Cancer 1 Br J Cancer 1 Breast Cancer (Dove Med Press) 4 Breast Cancer Res 2 Breast Cancer Res Treat 2 Breast J 1 Cancer Chemother Pharmacol 1 Cancer Lett 1 Cancer Res 1 Carcinogenesis 4 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 2 Eur J Surg Oncol 1 Eur Radiol 1 Int J Cancer 1 Int J Oncol 1 J Clin Invest 1 J Clin Oncol 2 J Natl Cancer Inst 1 J Pathol 4 Oncogene 1 Oncol Rep 2 PLoS Comput Biol 6 PLoS One 1 Proc Natl Acad Sci U S A 1 Science

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Surg

1. SATYANANDA V, Ozao-Choy J, Dauphine C, Chen KT, et al
   Effect of the Affordable Care Act on breast cancer presentation at a safety net hospital.
   Am J Surg. 2019 Jan 17. pii: S0002-9610(18)31369.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. ROBSON ME, Tung N, Conte P, Im SA, et al
   OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
   Ann Oncol. 2019 Jan 23. pii: 5299440. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
3. DELALOGE S, Cella D, Ye Y, Buyse M, et al
   Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.
   Ann Oncol. 2019 Jan 23. pii: 5299438. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

4. SHAH NM, Scott DM, Kandagatla P, Moravek MB, et al
   Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer.
   Ann Surg Oncol. 2019 Jan 24. pii: 10.1245/s10434-019-07156.
   PubMed     Text format     Abstract available
   
   
5. TADROS AB, Wen HY, Morrow M
   Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
   Ann Surg Oncol. 2018;25:3158-3164.
   PubMed     Text format     Abstract available
   
   
6. MAMOUNAS EP
   Omitting Surgery in Complete Responders After Neoadjuvant Chemotherapy: The Quest Continues.
   Ann Surg Oncol. 2018;25:3119-3122.
   PubMed     Text format    
   
   

   
   BMC Cancer

7. MUMIN NH, Drobnitzky N, Patel A, Lourenco LM, et al
   Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
   BMC Cancer. 2019;19:102.
   PubMed     Text format     Abstract available
   
   
8. SCHAFFAR R, Belot A, Rachet B, Woods L, et al
   On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.
   BMC Cancer. 2019;19:107.
   PubMed     Text format     Abstract available
   
   
9. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
   The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
   BMC Cancer. 2019;19:110.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

10. OWEN LJ, Monaghan PJ, Armstrong A, Keevil BG, et al
    Oestradiol measurement during fulvestrant treatment for breast cancer.
    Br J Cancer. 2019 Jan 25. pii: 10.1038/s41416-019-0378.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

11. AYOUB NM, Al-Shami KM, Yaghan RJ
    Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
    Breast Cancer (Dove Med Press). 2019;11:53-69.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

12. BHAT K, Sandler K, Duhachek-Muggy S, Alli C, et al
    Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
    Breast Cancer Res. 2019;21:17.
    PubMed     Text format     Abstract available
    
    
13. POGUE BW
    Can novel technologies improve breast conserving surgery?
    Breast Cancer Res. 2018;20:85.
    PubMed     Text format    
    
    
14. GHAFFARI A, Hoskin V, Turashvili G, Varma S, et al
    Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Breast Cancer Res. 2019;21:12.
    PubMed     Text format     Abstract available
    
    
15. XIAO Y, Xia J, Li L, Ke Y, et al
    Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.
    Breast Cancer Res. 2019;21:16.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

16. FATEHI S, Maasoumi R, Atashsokhan G, Hamidzadeh A, et al
    The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Jan 30. pii: 10.1007/s10549-019-05140.
    PubMed     Text format     Abstract available
    
    
17. SZIJGYARTO Z, Flach KD, Opdam M, Palmieri C, et al
    Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Breast Cancer Res Treat. 2019 Jan 24. pii: 10.1007/s10549-018-05110.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

18. CHIANG PH, Tang FH, Tsai EM, Chang YC, et al
    Hormone therapy as risk factor of breast cancer modulated by diagnostic and lifestyle risk factors in Taiwan-A National Cohort study.
    Breast J. 2019 Jan 30. doi: 10.1111/tbj.13184.
    PubMed     Text format    
    
    
19. KATAOKA A, Sawaki M, Okumura S, Onishi S, et al
    Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy.
    Breast J. 2019 Jan 30. doi: 10.1111/tbj.13194.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

20. CAMPONE M, Bachelot T, Penault-Llorca F, Pallis A, et al
    A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jan 25. pii: 10.1007/s00280-018-03765.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

21. CHO TM, Kim JY, Kim YJ, Sung D, et al
    C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cancer Lett. 2019 Jan 28. pii: S0304-3835(19)30049.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

22. STEIN RG, Ebert S, Schlahsa L, Scholz CJ, et al
    Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.
    Cancer Res. 2019 Jan 28. pii: 0008-5472.CAN-18-0387.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

23. MUNIRAJ N, Siddharth S, Nagalingam A, Walker A, et al
    Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells.
    Carcinogenesis. 2019 Jan 29. pii: 5303994. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

24. BONNER SN, Clark C, Keating NL, Kouri EM, et al
    Examining Associations of Racial Residential Segregation With Patient Knowledge of Breast Cancer and Treatment Receipt.
    Clin Breast Cancer. 2018 Dec 8. pii: S1526-8209(18)30417.
    PubMed     Text format     Abstract available
    
    
25. NOUR ELDIN EEM, El-Readi MZ, Nour Eldein MM, Alfalki AA, et al
    8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.
    Clin Breast Cancer. 2018 Dec 21. pii: S1526-8209(18)30631.
    PubMed     Text format     Abstract available
    
    
26. ORTEGA V, Anton A, Garau I, Afonso N, et al
    Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Clin Breast Cancer. 2018 Dec 20. pii: S1526-8209(17)30144.
    PubMed     Text format     Abstract available
    
    
27. KAPILA AK, Herd A, Knife N, Chaplin P, et al
    A Prospective Cohort Study on the Impact of Reflexology in Patients With Breast Cancer Using the MYCaW Scale.
    Clin Breast Cancer. 2018 Dec 19. pii: S1526-8209(18)30423.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

28. ELMI A, Makvandi M, Weng CC, Hou C, et al
    Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-2769.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

29. YONEMORI K, Shimomura A, Yasojima H, Masuda N, et al
    A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    Eur J Cancer. 2019;109:84-91.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

30. METS EJ, Chouairi FK, Gabrick KS, Avraham T, et al
    Persistent disparities in breast cancer surgical outcomes among hispanic and African American patients.
    Eur J Surg Oncol. 2019 Jan 17. pii: S0748-7983(19)30039.
    PubMed     Text format     Abstract available
    
    
31. OJALA K, Meretoja TJ, Mattson J, Leidenius MHK, et al
    Surgical treatment and prognosis of breast cancer in elderly - A population-based study.
    Eur J Surg Oncol. 2019 Jan 21. pii: S0748-7983(19)30042.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

32. HAN L, Zhu Y, Liu Z, Yu T, et al
    Radiomic nomogram for prediction of axillary lymph node metastasis in breast cancer.
    Eur Radiol. 2019 Jan 30. pii: 10.1007/s00330-018-5981.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

33. JANNING M, Muller V, Vettorazzi E, Cubas-Cordova M, et al
    Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32163.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

34. WANG ZF, Sun WY, Yu DH, Zhao Y, et al
    Rotundic acid enhances the impact of radiological toxicity on MCF-7 cells through the ATM/p53 pathway.
    Int J Oncol. 2018;53:2269-2277.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Invest

35. CUI B, Luo Y, Tian P, Peng F, et al
    Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells.
    J Clin Invest. 2019 Jan 28. pii: 121685. doi: 10.1172/JCI121685.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

36. HAMY AS, Tury S, Wang X, Gao J, et al
    Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

37. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    PubMed     Text format    
    
    
38. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Pathol

39. KRSTIC M, Kolendowski B, Cecchini MJ, Postenka CO, et al
    TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
    J Pathol. 2019 Jan 29. doi: 10.1002/path.5245.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

40. WOOSLEY AN, Dalton AC, Hussey GS, Howley BV, et al
    TGFbeta promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0703.
    PubMed     Text format     Abstract available
    
    
41. ZHAO Y, Qiao S, Hou X, Tian H, et al
    Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells.
    Oncogene. 2019 Jan 30. pii: 10.1038/s41388-019-0719.
    PubMed     Text format     Abstract available
    
    
42. CHOUCAIR A, Pham TH, Omarjee S, Jacquemetton J, et al
    The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0694.
    PubMed     Text format     Abstract available
    
    
43. ZHOU XL, Zhu CY, Wu ZG, Guo X, et al
    The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0698.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

44. MA Z, Liu X, Zhang Q, Yu Z, et al
    Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROSmediated PI3K/AKT signaling pathway.
    Oncol Rep. 2019;41:811-818.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Comput Biol

45. BISMEIJER T, Canisius S, Wessels LFA
    Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.
    PLoS Comput Biol. 2018;14:e1006520.
    PubMed     Text format     Abstract available
    
    
46. LYU Y, Xue L, Zhang F, Koch H, et al
    Condition-adaptive fused graphical lasso (CFGL): An adaptive procedure for inferring condition-specific gene co-expression network.
    PLoS Comput Biol. 2018;14:e1006436.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

47. PIETERS HC, Green E, Khakshooy S, Sleven M, et al
    A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy.
    PLoS One. 2019;14:e0210972.
    PubMed     Text format     Abstract available
    
    
48. CHITAPANARUX I, Nobnop W, Tippanya D, Sripan P, et al
    Clinical outcomes and dosimetric study of hypofractionated Helical TomoTherapy in breast cancer patients.
    PLoS One. 2019;14:e0211578.
    PubMed     Text format     Abstract available
    
    
49. 
    Expression of Concern: Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
    PLoS One. 2019;14:e0211655.
    PubMed     Text format    
    
    
50. WILLIAMS LA, Casbas-Hernandez P, Nichols HB, Tse CK, et al
    Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.
    PLoS One. 2019;14:e0211488.
    PubMed     Text format     Abstract available
    
    
51. HONG JH, Ko YH, Kang K
    RNA variant identification discrepancy among splice-aware alignment algorithms.
    PLoS One. 2018;13:e0201822.
    PubMed     Text format     Abstract available
    
    
52. MICHEL LL, Sommer L, Gonzalez Silos R, Lorenzo Bermejo J, et al
    Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index.
    PLoS One. 2019;14:e0211337.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

53. CHEN IX, Chauhan VP, Posada J, Ng MR, et al
    Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
    Proc Natl Acad Sci U S A. 2019 Jan 30. pii: 1815515116.
    PubMed     Text format     Abstract available
    
    

    
    Science

54. 
    Erratum for the Report "PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D" by E. Toska, H. U. Osmanbeyoglu, P. Castel, C. Chan, R. C. Hendrickson, M. Elkabets, M. N. Dickler, M. Scaltriti, C. S.
    Science. 2019;363.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: